tislelizumab + nab-paclitaxel + cisplatin

This combination therapy is a chemoimmunotherapy regimen being investigated by Sun Yat-sen University for the treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), specifically cases with skull base invasion. The regimen consists of **tislelizumab**, a humanized IgG4 monoclonal antibody designed to bind to the programmed cell death protein 1 (PD-1) receptor and inhibit its interaction with PD-L1 and PD-L2; **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), a microtubule inhibitor; and **cisplatin**, a platinum-based DNA alkylating agent. In the clinical trial setting, this combination is utilized as a neoadjuvant therapy to reduce tumor volume and improve surgical resectability, followed by surgery, (chemo)radiotherapy, and adjuvant tislelizumab monotherapy. The approach aims to exploit the synergistic potential of cytotoxic chemotherapy and immune checkpoint inhibition to enhance pathological response rates and long-term survival in high-risk HNSCC patients.

Brand names

TevimbraAbraxane

Other names

tislelizumab + albumin-bound paclitaxel + cisplatintislelizumab + nab-paclitaxel + cisplatin regimen